附註:Includes bibliographical references (pages 281-283) and index.
Introduction; PART ONE: BIOHYPE; 1 The Longest Search; 2 Rare Profits; 3 The Source of the New Machine; PART TWO: DIRECTED RESEARCH; 4 A Public-Private Partnership; 5 The Divorce; 6 Breakthrough!; 7 The Failed Crusade?; PART THREE: BIG PHARMA; 8 Me Too!; 9 The 800 Million Pill; 10 The Future of Drug Innovation; Notes; Bibliography; Acknowledgments; Index; A; B; C; D; E; F; G; H; I; J; K; L; M; N; O; P; Q; R; S; T; U; V; W; X; Y; Z.
摘要:"Drug companies insist that [prescription drug] prices reflect the millions they invest in research and development ... Merrill Goozner contends that American taxpayers are in fact footing the bill twice: once by supporting government-funded research and again by paying high prices for prescription drugs. Goozner demonstrates that almost all of the important and life-saving new drugs of the past quarter-century actually originated from research at taxpayer-funded universities and the National Institutes of Health ... [Goozner] suggests ways that the government's role in testing new medicines could be expanded to eliminate private-sector waste driving up the cost of existing drugs--p. [2] of jacket.
